A weekly newsletter for quality and training leaders in pharma and biotech.
Subscribe →The most significant FDA policy shift since 1962 eliminates the two-trial default. Manufacturing teams now have 18–24 fewer months to reach commercial readiness. Here’s what that means for your floor.
$5.7 billion in new facilities. 47% more layoffs. Over 2,000 specialized roles with no pipeline to fill them. Where are the workers coming from?
The FDA found contamination dating back to 2022 that was never investigated. But the real story isn’t one facility. It’s the five 483 trends showing up everywhere.